Annesha White

Dr. Annesha White

College of Pharmacy, Dept. of Pharmacotherapy, University of North Texas Health Science Center, Fort Worth, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
Annesha WhiteAnnesha White
Annesha White
KFKimberly G Fulda
Kimberly G Fulda
RBRachel Blythe
Rachel Blythe
MCMichelle Anne Chui
Michelle Anne Chui
EREmily Reeve
Emily Reeve
YXYan Xiao
Yan Xiao
Over 4 billion prescriptions are dispensed each year to patients in the United States, with the number of prescriptions continuing to increase. There is a growing recognition of pharmacists’ potent...

31 July 2020 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
MSMeenakshi Srinivasan
Meenakshi Srinivasan
Annesha WhiteAnnesha White
Annesha White
ACAyyappa Chaturvedula
Ayyappa Chaturvedula
VVValvanera Vozmediano
Valvanera Vozmediano
SSStephan Schmidt
Stephan Schmidt
LWLa’mArcus T. Wingate
La’mArcus T. Wingate
Pharmacometrics is the science of quantifying the relationship between the pharmacokinetics and pharmacodynamics of drugs in combination with disease models and trial information to aid in drug development and dosing optimization for clinical practice. Considering the variability in the dose–concentration–effect relationship of drugs, an opportunity exists in linking pharmacokinetic and pharmacodynamic model-based estimates with pharmacoeconomic models. This link may provide early estimates of the cost effectiveness of drug therapies, thus informing late-stage drug development, pricing, and reimbursement decisions. Published case studies have demonstrated how integrated pharmacokinetic–pharmacodynamic–pharmacoeconomic models can complement traditional pharmacoeconomic analyses by identifying the impact of specific patient sub-groups, dose, dosing schedules, and adherence on the cost effectiveness of drugs, thus providing a mechanistic basis to predict the economic value of new drugs. Greater collaboration between the pharmacoeconomics and pharmacometrics community can enable methodological improvements in pharmacokinetic–pharmacodynamic–pharmacoeconomic models to support drug development.

9 July 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
Annesha WhiteAnnesha White
Annesha White
ETErika Thompson
Erika Thompson
SKSolyi Kim
Solyi Kim
JOJanice A. Osei
Janice A. Osei
KFKimberly G Fulda
Kimberly G Fulda
YXYan Xiao
Yan Xiao
Preventable adverse drug events (ADEs) remain a significant threat in community settings, a challenge that is critical in community pharmacy settings where continuity of care and healthcare access can be limited. This qualitative study explored the perspectives of 13 community pharmacists through focus groups and interviews to identify barriers and propose solutions to enhance their role in patient care. Pharmacists emphasized their critical position in ensuring safe medication use, particularly for older adults managing multiple chronic conditions. Key findings revealed five themes: (1) defining medication safety as minimizing risk and empowering patients; (2) characteristics of the “perfect patient,” including medication awareness and proactive engagement; (3) the pharmacist’s role in detecting and resolving medication-related problems; (4) systemic barriers such as time constraints, lack of access to patient records, insufficient privacy, and undervaluation of pharmacists’ roles; and (5) proposed solutions including private counseling areas, increased staffing, integrated electronic health records, and legislative recognition of pharmacists as healthcare providers. Strengthening collaboration with physicians and empowering patients through education were also highlighted as key strategies. These findings underscore the need for systemic changes—especially in light of lessons learned during the pandemic—to support pharmacists in delivering comprehensive medication management and improving patient safety.

1 December 2021 in Epilepsy & Behavior
Verified
Journal Article
Open access
SASeri Anderson
Seri Anderson
JMJosephine Mauskopf
Josephine Mauskopf
STSandra E. Talbird
Sandra E. Talbird
Annesha WhiteAnnesha White
Annesha White
MSMeenakshi Srinivasan
Meenakshi Srinivasan
To show the impact of drug–drug interactions (DDIs) associated with co-administration of enzyme-inducing (EI) antiseizure medications and oral contraceptives (OCs) on the annual number of unintended pregnancies, their outcomes, and their associated costs in the United States (US). A Microsoft Excel pregnancy-outcomes model was developed to determine the impact of DDIs in women who take an OC as well as an EI antiseizure medication known to lower the effectiveness of the OC in preventing pregnancy. The model compared the number of unintended pregnancies, the expected pregnancy outcomes, and associated costs in women taking an OC and an EI medication with a matched cohort of women who took an OC and an enzyme-neutral (EN) antiseizure medication that is known not to interact with OCs. The model perspectives were patients and third-party payers in the US. Unintended pregnancy rates, pregnancy outcomes, and cost inputs for the model were taken from published studies. The results of the analysis showed an estimated increase in the annual number of unintended pregnancies in the US of 503 (a change from 1151 to 1654), an increase of 44.7%, for the estimated 71,922 women currently taking an OC plus an EI medication in the US when compared with a matched cohort taking an OC plus an EN medication. This resulted in an estimated annual healthcare cost increase of $3 million, which is an increase of 5.5% in the annual costs for contraception and pregnancy care. A scenario analysis showed that the annual number of unintended pregnancies could be lower (575 vs 1654) for a matched cohort of women taking EI medications and using a copper intrauterine device, a highly effective and nonhormonal form of contraception, rather than an OC. Physicians treating women of reproductive age for epilepsy who wish to avoid pregnancy should consider the potential for DDIs that might result in unintended pregnancies. Thus, physicians should alert women using EI medications for epilepsy control to the increased potential for unintended pregnancies if they use OCs for contraception.

23 September 2025 in Journal of Patient Safety
Verified
Journal Article
Open access
RYRichard A. Young
Richard A. Young
YXYan Xiao
Yan Xiao
KFKimberly G Fulda
Kimberly G Fulda
Annesha WhiteAnnesha White
Annesha White
AGAyse P. Gurses
Ayse P. Gurses
Objectives: Our objective was to develop an in-depth understanding of the barriers and facilitators for medication safety in primary care by synthesizing findings from a multiyear, multisite study of care teams, pharmacists, and patients, using Safety-I and Safety-II lenses. Methods: We used mixed methods, including a systematic literature review and interviews on medication use in ambulatory primary care. We synthesized the findings using Safety-I and Safety-II lenses to identify safety challenges and strategies. Results: Published challenges and strategies were mostly framed through a Safety-I lens: establishing ever-expanding best practice algorithms and using them to decrease variability. In contrast, our analysis of patient and professional perspectives revealed that medication safety in ambulatory settings is undermined by the complexities of distributed work systems including poorly implemented safety checks; limited support for self-management; weak safety infrastructure; conflicting interests; and external forces beyond the control of patients and primary care professionals. We also identified actions by clinicians and pharmacists to improve medication safety that fall outside traditional compliance-focused Safety-I strategies. These actions were often initiated to overcome barriers in distributed work systems, highlighting the importance of Safety-II strategies in primary care. Conclusions: This study revealed a fundamental limitation in applying Safety-I principles to primary care medication safety, particularly the assumption that all system defects can be feasibly fixed. Given the complex realities of primary care, a complementary Safety-II perspective is essential, as it recognizes the agency of professionals and patients in managing risks within distributed work systems affected by uncontrollable external forces.

20 March 2021 in Health Economics Review
Verified
Journal Article
Open access
PDF file
Annesha WhiteAnnesha White
Annesha White
MSMeenakshi Srinivasan
Meenakshi Srinivasan
LWLa Marcus Wingate
La Marcus Wingate
SPSamuel Peasah
Samuel Peasah
MFMarc Fleming
Marc Fleming
Background: Disease-specific registries, documenting costs and probabilities from pharmacoeconomic studies along with health state utility values from quality-of-life studies could serve as a resource to guide researchers in evaluating the published literature and in the conduct of future economic evaluations for their own research. Registries cataloging economic evaluations currently exist, however they are restricted by the type of economic evaluations they include. There is a need for intervention-specific registries, that document all types of complete and partial economic evaluations and auxiliary information such as quality of life studies. The objective of this study is to describe the development of a pharmacoeconomic registry and provide best practices using an example of hormonal contraceptives.Methods: An expert panel consisting of researchers with expertise in pharmacoeconomics and outcomes research was convened and the clinical focus of the registry was finalized after extensive discussion. A list of key continuous, categorical and descriptive variables was developed to capture all relevant data with each variable defined in a data dictionary. A web-based data collection tool was designed to capture and store the resulting metadata. A keyword based search strategy was developed to retrieve the published sources of literature. Finally, articles were screened for relevancy and data was extracted to populate the registry. Expert opinions were taken from the panel at each stage to arrive at consensus and ensure validity of the registry.Results: The registry focused on economic evaluation literature of hormonal contraceptives used for contraception. The registry consisted of 65 articles comprising of 22 cost-effectiveness analyses, 9 cost-utility analyses, 7 cost-benefit analyses, 1 cost-minimization, 14 cost analyses, 10 cost of illness studies and 2 quality of life studies. The best practices followed in the development of the registry were summarized as recommendations. The completed registry, data dictionary and associated data files can be accessed in the supplementary information files.Conclusion: This registry is a comprehensive database of economic evaluations, including costs, clinical probabilities and health-state utility estimates. The collated data captured from published information in this registry can be used to identify trends in the literature, conduct systematic reviews and meta-analysis and develop novel pharmacoeconomic models.